Leerink Partnrs Issues Positive Forecast for SPRB Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Spruce Biosciences in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.24) for the quarter, up from their prior estimate of ($0.26). The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for Spruce Biosciences’ Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.41) EPS.

Spruce Biosciences (NASDAQ:SPRB) last released its earnings results on Tuesday, April 15th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.37). Spruce Biosciences had a negative return on equity of 62.10% and a negative net margin of 555.23%. The firm had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.50 million.

Separately, Royal Bank of Canada reduced their target price on shares of Spruce Biosciences from $1.50 to $0.50 and set a “sector perform” rating for the company in a research note on Wednesday, April 16th. Six investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, Spruce Biosciences presently has a consensus rating of “Hold” and a consensus price target of $2.17.

Spruce Biosciences Stock Up 1.8 %

SPRB opened at $0.07 on Friday. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 0.01. Spruce Biosciences has a 1-year low of $0.06 and a 1-year high of $0.85. The business has a 50 day moving average of $0.23 and a 200-day moving average of $0.37. The stock has a market capitalization of $3.12 million, a price-to-earnings ratio of -0.08 and a beta of 2.49.

Hedge Funds Weigh In On Spruce Biosciences

An institutional investor recently bought a new position in Spruce Biosciences stock. Boothbay Fund Management LLC purchased a new stake in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 288,800 shares of the company’s stock, valued at approximately $121,000. Boothbay Fund Management LLC owned approximately 0.70% of Spruce Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 91.71% of the company’s stock.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.